Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

216.39B

Market cap216.39B

Price-Earnings ratio

13.66

Price-Earnings ratio13.66

Dividend yield

2.58%

Dividend yield2.58%

Average volume

31.24M

Average volume31.24M

High today

$51.09

High today$51.09

Low today

$48.91

Low today$48.91

Open price

$50.17

Open price$50.17

Volume

30.10M

Volume30.10M

52 Week high

$93.80

52 Week high$93.80

52 Week low

$43.08

52 Week low$43.08

NVO News

TipRanks 25m

‘Blatant Attack’: HIMS Stock Plunges as Novo Lawsuit Triggers Analyst Price Target Cuts

Shares of Hims & Hers Health (HIMS) fell about 16% on Monday, extending last week’s losses following a regulatory crackdown on its non-FDA-approved compounds. T...

Simply Wall St 6h

Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside

Novo Nordisk (NYSE:NVO) has filed a lawsuit against Hims & Hers, alleging patent infringement tied to compounded oral semaglutide products. The case centers on...

The Motley Fool 8h

Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA scrutiny. Expand NYSE : HIMS Hims...

Analyst ratings

53%

of 34 ratings

Buy

52.9%

Hold

35.3%

Sell

11.8%

More NVO News

Nasdaq 9h

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?

Key Points On Friday, the U.S. Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 ingredients in compounded drugs not approved...

Cheddar 11h

Novo Nordisk Sues Hims Over Copycat Wegovy

Novo Nordisk is suing telehealth company Hims & Hers, accusing it of illegally mass marketing cheaper, unapproved compounded versions of Wegovy....

Nasdaq 11h

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?

Key Points Eli Lilly has been a growth beast and its top line may soar by as much as 27% this year. Novo Nordisk is bracing for a potential double-digit decli...

Benzinga 12h

FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast

• Hims & Hers Health stock is at significant support. What’s pressuring HIMS? What Happened Last Thursday, Hims & Hers Health announced an expansion of its we...

Benzinga 13h

Hims & Hers Under Fire, Stock Tanks on Federal Crackdown, Patent War

Shares of Hims & Hers crashed to new 52-week lows on Monday, under the weight of much uncertainty. HIMS stock is dropping. See the chart and price action here....

The Motley Fool 13h

Why Novo Nordisk Stock Just Popped

Novo Nordisk is suing Hims & Hers -- but Hims & Hers already surrendered. Novo Nordisk (NVO +3.80%) is taking investors on another rollercoaster ride. Last wee...

CNBC 14h

FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims

A box of Wegovy pills arranged at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026. The Food and Drug Administration said Novo Nordisk 's TV advertise...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.